Hikma Debuts ePHEDrine Injection in U.S.

Hikma Pharmaceuticals PLC (Hikma), a global leader in pharmaceuticals, has introduced ePHEDrine Sulfate Injection, USP in a 25 mg/5 mL dosage for the U.S. market. Delivered in a prefilled syringe, the product is designed to treat clinically significant hypotension during anesthesia.

Market Presence and Impact

According to IQVIA, sales of ePHEDrine Sulfate Injection, USP, 25 mg/5 mL, reached approximately $17 million in the U.S. during the 12 months ending October 2024.

Commitment to Patient Care

Hikma ranks among the top three suppliers of generic injectable medicines by volume in the U.S., offering over 170 essential medicines. The company continues to expand its portfolio, focusing on developing new dosage forms that improve healthcare accessibility and patient outcomes.

This launch highlights Hikma’s dedication to addressing critical medical needs and providing reliable, high-quality solutions for healthcare providers and their patients.